Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shenzhen Hepalink Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Mar. 2026 was $660.5 Mil.
Shenzhen Hepalink Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $69.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co EV-to-EBIT Related Terms
Shenzhen Hepalink Pharmaceutical Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co EV-to-EBIT Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co EV-to-EBIT vs Drug Manufacturers Industry
Shenzhen Hepalink Pharmaceutical Group Co's current Enterprise Value is $2,082.0 Mil.
Shenzhen Hepalink Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $69.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a EV-to-EBIT of 29.90 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is near median its historical median of 28.23. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #485 out of 682 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is Shenzhen Hepalink Pharmaceutical Group Co's EV-to-EBIT too high?
Shenzhen Hepalink Pharmaceutical Group Co's current EV-to-EBIT of 29.90 is near median its 10-year median of 28.23. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Shenzhen Hepalink Pharmaceutical Group Co's value of 29.90 is 88.6% above this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #485 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #485 out of 682 companies for EV-to-EBIT. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Shenzhen Hepalink Pharmaceutical Group Co's value of 29.90 is 88.6% above this benchmark. While the company's 10-year median is 28.23 vs. the industry median of 15.86, Shenzhen Hepalink Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current EV-to-EBIT of 29.90 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current EV-to-EBIT is 29.90, which is near median its own 10-year median of 28.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current EV-to-EBIT of 29.90. The stock's GF Value™ is $0.50, compared to a current price of $0.47 — trading 6.1% below its estimated fair value. The current EV-to-EBIT is 29.90, which is near median its 10-year median of 28.23 and 88.6% above the Drug Manufacturers industry median of 15.86. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current EV-to-EBIT is 29.90 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 6.1% below its estimated GF Value™ of $0.50.
Key valuation signals for SHEZF:
EV-to-EBIT: 29.90 (near median its 10-year median of 28.23)
GF Value™: $0.50 vs. price of $0.47 (6.1% below fair value)
Industry Position: 88.6% above the Drug Manufacturers median (#485 of 682)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
72GF Score
Get the complete analysis for SHEZF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
